WHAT IS CLAIMED:

1. An integrated viral complex, the complex comprising:

(a) a plurality of intact cell membranes, each of said intact cell membranes belonging to a non-viable cell; and

(b) a plurality of viable virions, a majority of said virions of said plurality of viable virions contained within said intact cell membrane belonging to said plurality of intact cell membranes.

2. The integrated viral complex of claim 1, wherein said virions are DNA virions,

3. The integrated viral complex of claim 2, wherein said DNA virions are double stranded DNA virions,

4. The integrated viral complex of claim 3, wherein said double stranded DNA virions belong to the herpes viruses.

5. The integrated viral complex of claim 4, wherein said herpes virus is Marek's disease virus.

6. A pharmaceutical composition for vaccination, the pharmaceutical composition comprising:

(a) a plurality of intact cell membranes, each of said intact cell membranes belonging to a non-viable cell; and

(b) a plurality of viable virions, a majority of said virions of said plurality of viable virions contained within said intact cell membrane belonging to said plurality of intact cell membranes; and

(c) carriers and excipients.

7. The pharmaceutical composition of claim 6, supplied as an article of manufacture including packaging material and instructions for use.

8. The pharmaceutical composition of claim 6, wherein said virions are DNA virions,

9. The pharmaceutical composition of claim 8, wherein said DNA virions are double stranded DNA virions,

10. The pharmaceutical composition of claim 9, wherein said double stranded DNA virions belong to the herpes viruses.

11. The integrated viral complex of claim 10, wherein said herpes virus is Marek's disease virus.

12. A method for producing integrated viral complexes, the method comprising:

(a) growing a population of individual cells in culture;

(b) infecting said individual cells belonging to said population with an aliquot of viable virions so that a desired viral yield is achieved;

(c) transferring said population of individual cells characterized by said desired viral yield to a storage medium containing a cryoprotectant;

(d) storing said population of individual cells characterized by said desired viral yield at a temperature in the range of (–) 30 to (+) 8 degrees centigrade.

13. The method of claim 12, wherein said infecting employ a viral preparation selected from the group consisting of a cell free preparation and a cell associated preparation.

14. The method of claim 12, wherein said cryoprotectant includes at least one material selected from the group consisting of glycerol, DMSO, and sugars.

15. The method of claim 12, wherein said desired viral yield is in the range of 0.001 to 1 PFU/cell.

16. The method of claim 12, wherein said temperature in the range of (+) 2 to (+) 8 degrees centigrade.

17. The method of claim 12, further comprising:

(e) passaging said individual cells belonging to said population with said desired viral yield as a means of increasing a size of said population.

18. The method of claim 12, further comprising:

(e) reducing a volume of said storage medium so that a desired number of cells per unit volume is achieved.

19. The method of claim 12, further comprising:

(e) drying said population of individual cells.

20. A method of producing a pharmaceutical composition for vaccination, the method comprising:

(a) growing a population of individual cells in culture;

(b) infecting said individual cells belonging to said population with an aliquot of viable virions so that a desired viral yield is achieved;

(c) transferring said population of individual cells characterized by said desired viral yield to a storage medium containing a cryoprotectant;

(d) dividing said population of individual cells characterized by said desired viral yield into dosage portions suited for vaccination of a specified number of subjects; and

(e) storing said dosage portions at a temperature in the range of (–) 30 to (+) 8 degrees centigrade.

21. The method of claim 20, wherein said dosage portions each individually include a number of doses in the range of 1 to 1 million.

22. The method of claim 20, wherein said infecting employ a viral preparation selected from the group consisting of a cell free preparation and a cell associated preparation.

23. The method of claim 20, wherein said cryoprotectant includes at least one material selected from the group consisting of glycerol, DMSO, and sugars.

24. The method of claim 20, wherein said desired viral yield is in the range of 0.001 to 1 PFU/cell.

25. The method of claim 20, wherein said temperature in the range of (+) 2 to (+) 8 degrees centigrade.

26. The method of claim 20, further comprising:

(f) passaging said individual cells belonging to said population with said desired viral yield as a means of increasing a size of said population.

27. The method of claim 20, further comprising:

(f) reducing a volume of said storage medium so that a desired number of cells per unit volume is achieved.

28. The method of claim 20, further comprising:

(f) drying said population of individual cells.

29. A method of vaccination which employs an integrated viral complex, the method comprising administering to a subject at least one dose of an amount of an integrated viral complex sufficient to elicit an active immune response in a subject.

30. The method of claim 29, wherein said subject is a member of an avian species.

31. The method of claim 29, wherein said integrated viral complex includes DNA virions,

32. The method of claim 29, wherein said DNA virions are double stranded DNA virions,

33. The method of claim 32, wherein said double stranded DNA virions belong to the herpes viruses.

34. The method of claim 32, wherein said herpes virus is Marek's disease virus.

35. The method of claim 29, wherein said administration is conducted *in ovo*.

36. The method of claim 29, wherein said administration is conducted via injection or from 1 day of age.